Condition: Large B Cell Diffuse Lymphoma · Mantle Cell Lymphoma (MCL) · Follicular Lymphoma ( FL) · Sponsor: Sun Yat-sen University
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
This description comes directly from the study's public registry record.
Qingqing Cai, MD. PhD · 02087342823 · caiqq@sysucc.org.cn
Yi Xia, MD. PhD · 02087342823 · xiayi@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Universitiy Cancer Center | Guangzhou, China | Recruiting |
| Fifth Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Not Yet Recruiting |
| Guangzhou overseas Chinese hospital | Guangzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07077512